Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified
Conditions
Brief summary
This phase II trial studies the effects of luspatercept with or without hydroxyurea in treating patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts. Biological therapies, such as luspatercept, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Hydroxyurea may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving luspatercept with or without hydroxyurea may help doctors determine what doses of the combination is safe for patients to take and how the disease responds to the treatment.
Detailed description
PRIMARY OBJECTIVE: I. To document the erythroid response rate assessed as per the 2015 International Working Group (IWG) myelodysplastic (MDS)/myeloproliferative neoplasms (MPN) response criteria. SECONDARY OBJECTIVES: I. To document response duration, time to acute myeloid leukemia (AML) transformation, AML-free survival (LFS) and overall survival (OS) in patients with MDS/MPN-with ring sideroblasts (RS) and thrombocytosis (T) and MDS/MPN-unclassifiable (U)U with RS. II. To document safety of luspatercept (luspatercept-aamt) in patients with MDS/MPN-RS-T and MDS/MPN-U with RS. EXPLORATORY OBJECTIVE: I. To assess overall health-related quality of life as measured by Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO). CORRELATIVE RESEARCH OBJECTIVE: I: To find an effective biomarker of response to luspatercept-aamt. OUTLINE: Patients are assigned to 1 of 2 cohorts. COHORT A: Patients receive luspatercept subcutaneously (SC) on day 1. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow biopsy and aspirate at baseline and on study. COHORT B: Patients receive luspatercept SC on day 1 and hydroxyurea orally (PO) on days 1-21. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow biopsy and aspirate at baseline and on study. After completion of study treatment, patients are followed up every 3 months.
Interventions
PROCEDUREBiospecimen Collection
Undergo blood sample collection
PROCEDUREBone Marrow Aspiration
Undergo bone marrow biopsy and aspirate
PROCEDUREBone Marrow Biopsy
Undergo bone marrow biopsy and aspirate
DRUGHydroxyurea
Given PO
BIOLOGICALLuspatercept
Given SC
OTHERQuestionnaire Administration
Ancillary studies
Sponsors
Mayo Clinic
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>= 18 years * Patients with a World Health Organization(WHO)-defined diagnosis of MDS/MPN-RS-T or MDS/MPN-U with \>= 15% RS * Prior treatment with lenalidomide, hypomethylating agents, immunosuppressive therapy, erythropoietin stimulating agents (ESA) or investigational agent is allowed as long as patients have not received luspatercept-aamt or sotatercept. If there is prior history of investigational agent, there should be an interval equivalent to at least four elimination half-lives of the agent prior to enrollment. Note: For patients who have received prior lenalidomide, hypomethylating agents, or immunosuppressive therapy, there must be \>= 6 weeks since the last dose before luspatercept-aamt treatment is started * Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2 * Requirement of red blood cell transfusions (\>= 2 unit =\< 8-weeks prior to registration) OR symptomatic anemia with hemoglobin \< 9.5 g/dL OR hematocrit \< 30% (as long as there is documentation of adequate iron stores (ferritin \> 50 mg/L) =\< 5 weeks prior to registration). Symptomatic anemia is defined as fatigue with or without exertion, shortness of breath with or without exertion, or decrease in exercise tolerance * Hemoglobin =\< 9.5 g/dL (obtained =\< 14 days prior to registration) * Total bilirubin =\< 1.5 x upper limit of normal (ULN) (obtained =\< 14 days prior to registration) * Alanine aminotransferase (ALT) and aspartate transaminase (AST) =\< 3 x ULN (=\< 5 x ULN for patients with liver involvement) (obtained =\< 14 days prior to registration) * Calculated creatinine clearance \>= 30 ml/min using the Cockcroft-Gault (obtained =\< 14 days prior to registration) * Females of childbearing potential (FCBP) defined as a sexually mature woman who: * Has achieved menarche at some point * Has not undergone a hysterectomy or bilateral oophorectomy, or * Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months) and must: * Must have two negative urine or serum pregnancy tests as verified by the investigator prior to starting study therapy. A negative pregnancy test must be done =\< 7 days prior to registration. Patient must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the subject practices true abstinence from heterosexual contact * Either commit to true abstinence\*from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with highly effective, contraception without interruption during the study therapy (including dose interruptions), and for 84 days after discontinuation of study therapy * True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[eg, calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception) * Male participants must: * Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 84 days following investigational product discontinuation even if he has undergone a successful vasectomy * True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[eg, calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception) * Provide written informed consent * Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study) * Willingness to provide mandatory blood specimens for correlative research
Exclusion criteria
* Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects: * Pregnant persons * Nursing persons * Persons of childbearing potential who are unwilling to employ highly effective contraception * Any of the following prior therapies: * Surgery =\< 3 weeks prior to registration * Chemotherapy or other agents =\< 2 weeks prior to registration * Uncontrolled intercurrent non-cardiac illness including, but not limited to: * Ongoing or active infection * Uncontrolled hypertension (defined as systolic blood pressure \>= 140 mmHg or diagnostic blood pressure \>= 90 mmHg despite use of \>= 3 anti-hypertensive drugs at optimal doses) * Psychiatric illness/social situations * Dyspnea at rest due to complications of advanced malignancy or other disease that requires continuous oxygen therapy * Clinically significant (symptomatic) anemia either due to nutritional deficiencies or iron, vitamin B12, folate or gastrointestinal (GI) bleeding * Any other conditions that would limit compliance with study requirements * Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state (CD4 =\< 200 x 10\^6/L), are eligible for this trial * Receiving any other drug (except hydroxyurea) or investigational agent which would be considered as a treatment for the primary disease, that is, MDS/MPN-RS-T or MDS/MPN-U with RS =\< 2 weeks prior to registration * Other active malignancy =\< 3 years prior to registration. Patients on hormonal therapy for treated breast or prostate cancer are permitted if they meet other eligibility criteria * EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix. NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment (luteinizing hormone-releasing hormone (LHRH) agonists for prostate cancer, and treatment with bisphosphonates and receptor activator of nuclear factor kappa-B ligand \[RANKL\] inhibitors) for their cancer * History of myocardial infarction, stroke, embolism, deep vein or arterial thrombosis =\< 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Erythroid Response Rate | 8 weeks | Defined as the proportion of patients who achieve an erythroid response out of the total number of evaluable patients (i.e. eligible patients who received at least one dose of treatment on study). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events (AEs) | 3 months, 29 days | AEs as well as toxicities (AEs felt to be at least possibly related to study treatment) will be reported in the adverse events section of the report. The count of participants by cohort that were evaluated for address events is reported here. |
| Duration of Response | 69 days | Time from erythroid response to progression or death. |
| Time to Leukemic Transformation | 6 months | Will be evaluated and characterized within each cohort using the methods of Kaplan and Meier. |
| Leukemia-free Survival | From time of treatment to progression to acute myeloid leukemia or death from any cause, assessed up to 6 months | Will be evaluated and characterized within each cohort using the methods of Kaplan and Meier. |
| Overall Survival | 117 117 days [was intended to be 'Up to 6 months' (duration of treatment), but study terminated early due to slow accrual] | Will be evaluated and characterized within each cohort using the methods of Kaplan and Meier. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| All Patients Cohort A (luspatercept) patients receive luspatercept SC on day 1. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.\>
\> Cohort B (luspatercept, hydroxyurea) patients receive luspatercept SC on day 1 and hydroxyurea PO on days 1-21. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity. | 3 |
| Total | 3 |
Baseline characteristics
| Characteristic | All Patients |
|---|---|
| Age, Continuous | 69 years STANDARD_DEVIATION 6.08 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 3 Participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 1 | 0 / 2 |
| other Total, other adverse events | 1 / 1 | 2 / 2 |
| serious Total, serious adverse events | 1 / 1 | 0 / 2 |
Outcome results
Primary
Erythroid Response Rate
Defined as the proportion of patients who achieve an erythroid response out of the total number of evaluable patients (i.e. eligible patients who received at least one dose of treatment on study).
Time frame: 8 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A (Luspatercept) | Erythroid Response Rate | 0 proportion of participants |
| Cohort B (Luspatercept, Hydroxyurea) | Erythroid Response Rate | 0.5 proportion of participants |
Secondary
Duration of Response
Time from erythroid response to progression or death.
Time frame: 69 days
Population: All patients that achieved Erythroid response.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A (Luspatercept) | Duration of Response | 69 Days |
Secondary
Incidence of Adverse Events (AEs)
AEs as well as toxicities (AEs felt to be at least possibly related to study treatment) will be reported in the adverse events section of the report. The count of participants by cohort that were evaluated for address events is reported here.
Time frame: 3 months, 29 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort A (Luspatercept) | Incidence of Adverse Events (AEs) | 1 Participants |
| Cohort B (Luspatercept, Hydroxyurea) | Incidence of Adverse Events (AEs) | 2 Participants |
Secondary
Leukemia-free Survival
Will be evaluated and characterized within each cohort using the methods of Kaplan and Meier.
Time frame: From time of treatment to progression to acute myeloid leukemia or death from any cause, assessed up to 6 months
Population: No AML transformations were reported among the three patients on trial.
Secondary
Overall Survival
Will be evaluated and characterized within each cohort using the methods of Kaplan and Meier.
Time frame: 117 117 days [was intended to be 'Up to 6 months' (duration of treatment), but study terminated early due to slow accrual]
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A (Luspatercept) | Overall Survival | 87.0 days |
| Cohort B (Luspatercept, Hydroxyurea) | Overall Survival | NA days |
Secondary
Time to Leukemic Transformation
Will be evaluated and characterized within each cohort using the methods of Kaplan and Meier.
Time frame: 6 months
Population: No AML transformations were reported among the three patients on trial.